Boom-IBD Clinical Trial

ID#: NCT05414955

Age: 18 - 75 years

Gender: All

Healthy Subjects: No

Study Phase: N/A

Recruitment Status: Enrolling by invitation

Start Date: October 01, 2022

End Date: December 01, 2026

Summary: Feasibility study of neuromodulation in patients with IBD.
Eligibility: General

Inclusion Criteria:

- Male or female

- 18 to 75 years of age

- Diagnosed with Crohn's Disease or ulcerative colitis

- Ability and willingness to consent to participate by signing the informed consent form

- Ability to comply with the protocol and willingness to comply with all follow-up requirements

- Still have part or all of their colon General Exclusion Criteria (The subject must not meet ANY of the following criteria):

- Any significant medical condition that is likely to interfere with study procedures, device operation, or likely to confound the results of the study

- Any psychiatric or personality disorder at the discretion of the study investigator

- Any active bacterial infection with a risk of bacteremia or sepsis (e.g. presence of abscess)

- Active clostridium difficile infection of the colon

- Active cytomegalovirus (CMV) infection of the colon

- Evidence of colonic perforation

- Fulminant colitis requiring emergency surgery

- Microscopic, ischemic or infectious colitis

- Unresected neoplasia of the colon

- Colonic stricture unable to pass a colonoscope

- History of cancer including melanoma (except for localized skin cancers) within 2 years

- Participation in another clinical trial within the past 30 days of device implant

- Investigational drug for the treatment of inflammatory bowel disease within 6 months of device implant

- Inability to operate the patient programmer